Date: 2017-07-18
Type of information: Fundraising
Company: Eurofins Scientific (Luxembourg)
Investors:
Amount: € 65 million
Funding type: fundraising
Planned used:
- Eurofins Scientific intends to use the proceeds of the issuance for general corporate purposes, including refinancing some of its existing debt instruments, as well as to fund any further growth opportunity in-line with the Group’s strategy and objectives. The new bond further improves Eurofins’ liquidity position by lengthening its debt maturity profile.
Others:
- • On July 18, 2017, Eurofins Scientific announced that it has successfully raised € 650 million in its latest senior unsecured Euro bond public issuance. The bonds have a 7-year maturity (due 25 July 2024) and will bear an annual rate of 2.125%, the lowest coupon achieved by Eurofins since its debut senior Euro bond issuance in November 2013.
- The issue was more than 4x times over-subscribed. BofA Merrill Lynch and BNP Paribas acted as global coordinators and Crédit Agricole CIB, Natixis and UniCredit Bank acted as joint bookrunners for the transaction. The bonds will be listed from their issue date (25 July 2017) on the regulated market of the Luxembourg stock exchange (ISIN XS1651444140). The bonds are not registered under the US Securities Act of 1933 as amended (the “Securities Act”), and may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration.
Therapeutic area: Technology - Services
Is general: Yes
